#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention
Listen to the original audio · Transcribed with NVIDIA Parakeet · Timestamps stay in sync with the live audio
Hey everyone, welcome to the Drive Podcast. I'm your host, Peter Atia. This podcast, my website, and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen. It is extremely important to me to provide all of this content without relying on paid ads.
To do this, our work is made entirely possible by our members, and in return, we offer exclusive member-only content and benefits above and beyond what is available for free. If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. If you want to learn more about the benefits of our premium membership, head over to peterateiamd.com forward slash subscribe. Welcome to a special episode of the drive. In this episode, I take a slightly different approach where I'm going to walk you through a single topic in
depth, breaking down the science behind, in this case, a drug that caught my attention and has me very excited. The drug is called obacetrapib. So I'm going to explain what it is, why it's generating renewed interest in cardiovascular medicine, at least as a class of drug, and why the emerging data may also have implications for Alzheimer's disease, particularly for those who carry an E4 allele. So in this episode I'm going to discuss what obacetrapib is, how it works as a class of drug called a CETP inhibitor. The history of these drugs and why the previous versions of them have failed, in some cases, spectacularly, the key clinical trials behind obacetrapib and why they were designed, what they were designed to measure, the drugs' effect on the major lipid biomarkers, including LP litol A, all very interesting.
We already have this episode, so unlocking it is cheap and permanent: the full transcript (53 minutes, 8,804 words), segment and word-level timestamps, and .txt, .srt, .vtt and word-level JSON downloads, as many times as you like, forever.
No account needed, we create one from your checkout email. With credits it is 1 credit; packs start at 10 episodes for $5, and monthly plans are cheaper still.